Takeda Pharmaceutical
TAK
18.37
+0.27
+1.49%
Takeda Pharmaceutical
US · TAK
#400 by market cap
Listed 1970
18.37
+0.27
+1.49%
Live - 5344 symbols - heartbeat 506s ago
· 2026-10-08 07:37
Pre-market
18.37
0.00%
After-hours
18.37
0.00%
Overnight
18.34
-0.16%
- Market cap
- 58.68B
- P/E (TTM)i
- -55.67
- P/Bi
- 1.23
- EPSi
- -0.31
- Div yieldi
- 3.26%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on TAK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.9 percentage points.
Institutional ownership
- Held by institutions
- 51.48% -0.94pp
- Institutions
- 678 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund44.68%
Public Company2.83%
Sovereign Wealth Fund1.29%
Private Company1.24%
Hedge Fund0.69%
Government Pension Fund0.49%
Insurance Company0.20%
Individual/Insider0.12%
Other48.43%
Top holders as of 2026-09-15
BlackRock
9.15% · 292.05M sh
Nomura Asset Management
4.42% · 141.11M sh
Vanguard Capital Management, LLC
3.88% · 123.89M sh
Sumitomo Mitsui Trust Asset Management
3.11% · 99.22M sh
Capital Research
2.91% · 92.89M sh
Other
77.08%
Amova Asset Management
2.14% · 68.46M sh
Daiwa Asset Management
2.00% · 63.84M sh
Nissay Asset Management Corporation
1.55% · 49.50M sh
Sumitomo Mitsui Financial Group, Inc.
1.39% · 44.28M sh
Norges Bank Investment Management
1.29% · 41.31M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Christophe P. Weber | President, CEO & Representative Director | 0.05% |
| Andrew S. Plump | President of Research & Development and Representative Director | 0.02% |
| Julie Kim | President of the U.S. Business Unit & U.S. Country Head | 0.01% |
| Giles Platford | President of the Plasma-Derived Therapies Business Unit | 0.01% |
| Teresa Marie Bitetti | President of the Global Oncology Business Unit | 0.01% |
| Marcello Pignagnoli Agosti | Global Business Development Officer | 0.00% |
| Gabriele Ricci | Chief Data & Technology Officer | 0.00% |
| Lauren Duprey | Chief Human Resources Officer | 0.00% |
| Milano Furuta | President of Japan Pharma Business Unit | 0.00% |
| Farajallah Awny Botros | Chief Medical Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-13 | Lauren Duprey | Chief Human Resources Officer | Open Market Disposition | -34,535 | $18.54 |
| 2026-09-01 | Andrew S. Plump | President of Research & Development and Representative Director | Automatic Disposition | -116,191 | $18.49 |
| 2026-08-18 | Andrew S. Plump | President of Research & Development and Representative Director | Automatic Disposition | -19,651 | $18.49 |
| 2026-08-17 | Nicola Greenway | -- | Open Market Disposition | -12,980 | $18.11 |
| 2026-08-13 | Nicola Greenway | -- | Intent to Sell (Form 144) | -12,980 | $17.39 |
| 2026-08-10 | Elaine Shannon | President of Global Supply & Quality | Open Market Disposition | -20,363 | $17.55 |
| 2026-08-09 | Andrew S. Plump | President of Research & Development and Representative Director | Private Disposition | -165,393 | $17.10 |
| 2026-08-09 | Giles Platford | President of the Plasma-Derived Therapies Business Unit | Private Disposition | -31,083 | $17.10 |
| 2026-08-09 | Farajallah Awny Botros | Chief Medical Officer | Private Disposition | -14,006 | $17.10 |
| 2026-08-09 | Julie Kim | President of the U.S. Business Unit & U.S. Country Head | Private Disposition | -89,090 | $17.10 |
| 2026-08-09 | Teresa Marie Bitetti | President of the Global Oncology Business Unit | Private Disposition | -50,012 | $17.10 |
| 2026-08-09 | Ramy Ibrahim | -- | Private Disposition | -7,277 | $17.10 |
| 2026-08-09 | Lauren Duprey | Chief Human Resources Officer | Private Disposition | -47,586 | $17.10 |
| 2026-08-09 | Gabriele Ricci | Chief Data & Technology Officer | Private Disposition | -25,088 | $17.10 |
| 2026-08-09 | Marcello Pignagnoli Agosti | Global Business Development Officer | Private Disposition | -22,957 | $17.10 |
| 2026-08-09 | Elaine Shannon | President of Global Supply & Quality | Private Disposition | -3,978 | $17.10 |
| 2026-08-09 | Natalie Furney | Global General Counsel | Private Disposition | -30,868 | $17.10 |
| 2026-08-09 | Rhonda Pacheco | President of U.S. Business Unit | Private Disposition | -16,901 | $17.10 |
| 2026-08-09 | Nicola Greenway | -- | Private Disposition | -6,774 | $17.10 |
| 2026-08-09 | Nicola Greenway | -- | Open Market Disposition | -34,603 | $17.50–17.51 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:37:49 · For reference only, not investment advice and not tailored to your situation.